36 search results for: Chronic Spontaneous Urticaria
AD, PN, and CSU: Similar Inflammation, Distinct Itch
In this final video, Dr. Kim compares the shared and distinct pathophysiological features that drive itch in AD, PN, and CSU. He ties together the knowledge from earlier episodes, highlighting the similarities and differences in the mechanisms of itch across these diseases.
Diagnosing CSU: Hives, Angioedema, and Differential Diagnosis
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.
Expert Interview with Dr Jason Hawkes
Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.
The Clinical Presentation of CSU is Heterogeneous
Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management
Professors Netchiporouk and Hawkes discuss the clinical features and pathophysiology of CSU, at EADV 2025.
Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU
In this video from EADV 2025, Dr. Netchiporouk discusses the clinical features, diagnosis, and burden of CSU
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation
CSU is Associated With a High Burden and Impact on Quality of Life
Dr. Casale discusses delays in diagnosing CSU, the impact of severe itch on daily life and mental health, and the challenges in achieving remission.
How type 2 cytokines can amplify inflammatory response in CSU
Dr. Thomos Casale explores the role of Th2 inflammation in CSU, highlighting the impact of IgE autoantibodies and the need for targeted therapies against Th2 cytokines.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
ADVENT Forum 2025 Event Page
From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.
